Savara Inc (SVRA)

$6.37 +0.07 (1.11%)
Market Cap 1.18B
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,977,400
Avg Vol 1,964,466
Day's Range N/A - N/A
Shares Out 203.47M
Stochastic %K 88%
Beta 0.23
Analysts Strong Sell
Price Target $10.31

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
joe9
joe9 Dec. 4 at 11:28 PM
$SVRA Long time investor, i hope they don‘t do a buyout early, they dont need it with the recent financing..Savara has a chance to help Tens of thousands of people. The company is worth $5BILLION Plus.
1 · Reply
ghostdemon
ghostdemon Dec. 4 at 9:28 PM
$SPY $SVRA bruh I’m already up 30% in these calls
0 · Reply
Spacemonkey1
Spacemonkey1 Dec. 4 at 8:52 PM
$SVRA I just don’t think it would make sense for a buyout to occur at this juncture, I think that rumor is just an internet rumor
0 · Reply
Richterscale
Richterscale Dec. 4 at 7:40 PM
$SVRA Nothing crazy from call. Hope NDA comes this week to keep the bull running
0 · Reply
KPMD
KPMD Dec. 4 at 4:40 PM
$SVRA When you think about GMCSF, it is a component of almost all chemotherapies that’s delivered subcutaneously. There’s really nothing proprietary about the medication. In APAP patient the macrophages are dysfunctional respond extremely well to GMCSF. It’s very simple model , the medication directly to dysfunctional macrophages in the lung. 
0 · Reply
ckruel
ckruel Dec. 4 at 3:36 PM
$SVRA the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
Flydown
Flydown Dec. 4 at 11:16 AM
$SVRA i bet Evercore raises ita TP from 2 bucks to 7/8 bucks It was the only One that had such a low TP. Maybe that were convnced by Piper Sandler the day before Who always declared a TP of 16 bucks
1 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:28 AM
$SVRA enjoying this price action. Pending NDA submission but wondering if there is more to this...
0 · Reply
graphk1
graphk1 Dec. 3 at 10:03 PM
$SVRA took my eye off Mast Therapeutics when it was in my ira account. have held it out of spite...and now it looks like it might not go up on my wall of shame trades.
0 · Reply
dixiebull
dixiebull Dec. 3 at 9:41 PM
$RR ran to 4.24 so now we want 4 to hold for a move to 5 $VERI off watchlist got to 5.41, see if 5.25 holds for a move to 6 $SVRA got 6.61, we want 6 to hold now for a move to 7 $TARA ran up to 7.45, ending here at 6.81 vwap area. See if 6.65 holds for a move to 7 and 7.50 $TMC pushing to 8 now, if that 8 can break then 8.50/9
0 · Reply
Latest News on SVRA
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 3 days ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Nov 20, 2025, 4:05 PM EST - 14 days ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara: A High-Risk Opportunity

Nov 16, 2025, 6:35 AM EST - 19 days ago

Savara: A High-Risk Opportunity

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 22 days ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 4 weeks ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 5 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 5 weeks ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 5 weeks ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 5 weeks ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 5 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 6 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 7 weeks ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 7 weeks ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 7 weeks ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 9, 2025, 7:42 AM EDT - 2 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 2 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 2 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 3 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 3 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 3 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:05 AM EDT - 4 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Savara Announces New Employment Inducement Grant

Jul 18, 2025, 4:05 PM EDT - 4 months ago

Savara Announces New Employment Inducement Grant

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 28, 2025, 6:00 AM EDT - 6 months ago

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

May 27, 2025, 3:40 PM EDT - 6 months ago

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

May 27, 2025, 11:42 AM EDT - 6 months ago

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 27, 2025, 8:05 AM EDT - 6 months ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

joe9
joe9 Dec. 4 at 11:28 PM
$SVRA Long time investor, i hope they don‘t do a buyout early, they dont need it with the recent financing..Savara has a chance to help Tens of thousands of people. The company is worth $5BILLION Plus.
1 · Reply
ghostdemon
ghostdemon Dec. 4 at 9:28 PM
$SPY $SVRA bruh I’m already up 30% in these calls
0 · Reply
Spacemonkey1
Spacemonkey1 Dec. 4 at 8:52 PM
$SVRA I just don’t think it would make sense for a buyout to occur at this juncture, I think that rumor is just an internet rumor
0 · Reply
Richterscale
Richterscale Dec. 4 at 7:40 PM
$SVRA Nothing crazy from call. Hope NDA comes this week to keep the bull running
0 · Reply
KPMD
KPMD Dec. 4 at 4:40 PM
$SVRA When you think about GMCSF, it is a component of almost all chemotherapies that’s delivered subcutaneously. There’s really nothing proprietary about the medication. In APAP patient the macrophages are dysfunctional respond extremely well to GMCSF. It’s very simple model , the medication directly to dysfunctional macrophages in the lung. 
0 · Reply
ckruel
ckruel Dec. 4 at 3:36 PM
$SVRA the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
Flydown
Flydown Dec. 4 at 11:16 AM
$SVRA i bet Evercore raises ita TP from 2 bucks to 7/8 bucks It was the only One that had such a low TP. Maybe that were convnced by Piper Sandler the day before Who always declared a TP of 16 bucks
1 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:28 AM
$SVRA enjoying this price action. Pending NDA submission but wondering if there is more to this...
0 · Reply
graphk1
graphk1 Dec. 3 at 10:03 PM
$SVRA took my eye off Mast Therapeutics when it was in my ira account. have held it out of spite...and now it looks like it might not go up on my wall of shame trades.
0 · Reply
dixiebull
dixiebull Dec. 3 at 9:41 PM
$RR ran to 4.24 so now we want 4 to hold for a move to 5 $VERI off watchlist got to 5.41, see if 5.25 holds for a move to 6 $SVRA got 6.61, we want 6 to hold now for a move to 7 $TARA ran up to 7.45, ending here at 6.81 vwap area. See if 6.65 holds for a move to 7 and 7.50 $TMC pushing to 8 now, if that 8 can break then 8.50/9
0 · Reply
Superich888
Superich888 Dec. 3 at 6:42 PM
$SVRA … Told you, from 5,8 to $6,55
0 · Reply
RunnerSignals
RunnerSignals Dec. 3 at 5:35 PM
$SVRA $FIGS $ARWR $GSK $TER Not your average bounce… these names are in full breakout mode https://stocksrunner.com/news/2025-12-03-52-week-highs-surge-as-breakout-stocks-hit-fresh-peaks
0 · Reply
TeeMan123
TeeMan123 Dec. 3 at 5:17 PM
$SVRA we getting a buyout or what???
1 · Reply
Zeffanator2
Zeffanator2 Dec. 3 at 5:15 PM
$SVRA BOOOOm!!!!!
0 · Reply
dbr_island
dbr_island Dec. 3 at 4:38 PM
$SVRA there it goes….. 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
Flydown
Flydown Dec. 2 at 10:14 PM
$SVRA Insmed has €1.7 billion in liquidity, which means they're preparing for an acquisition. SVRA, by chance, is the perfect target given its size and organic growth in the pulmonary field. Stay tuned
1 · Reply
Superich888
Superich888 Dec. 2 at 8:47 PM
$SVRA …Fellings AH
0 · Reply
TeeMan123
TeeMan123 Dec. 2 at 7:43 PM
$SVRA beatville has some uncooked m&a chatter.. they’ve had a weak hit ratio but they just mentioned svra as a target
1 · Reply
Richterscale
Richterscale Dec. 2 at 7:28 PM
$SVRA there s some wild trading going on right now
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:15 PM
$SUIG $SUPN $SUPV $SVRA $SWKS proven Accuracy
0 · Reply
Richterscale
Richterscale Dec. 1 at 9:31 PM
$SVRA AH has 27k traded and it’s back to $6. I don’t think this stays under 6 very long
0 · Reply
Spacemonkey1
Spacemonkey1 Dec. 1 at 7:51 PM
$SVRA another wtf?!? day in the life of a Savara investor
0 · Reply